Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction.

Tiosano D, Baris HN, Chen A, Hitzert MM, Schueler M, Gulluni F, Wiesener A, Bergua A, Mory A, Copeland B, Gleeson JG, Rump P, van Meer H, Sival DA, Haucke V, Kriwinsky J, Knaup KX, Reis A, Hauer NN, Hirsch E, Roepman R, Pfundt R, Thiel CT, Wiesener MS, Aslanyan MG, Buchner DA.

PLoS Genet. 2019 Apr 29;15(4):e1008088. doi: 10.1371/journal.pgen.1008088. eCollection 2019 Apr.

2.

Biallelic Expression of Mucin-1 in Autosomal Dominant Tubulointerstitial Kidney Disease: Implications for Nongenetic Disease Recognition.

Knaup KX, Hackenbeck T, Popp B, Stoeckert J, Wenzel A, Büttner-Herold M, Pfister F, Schueler M, Seven D, May AM, Halbritter J, Gröne HJ, Reis A, Beck BB, Amann K, Ekici AB, Wiesener MS.

J Am Soc Nephrol. 2018 Sep;29(9):2298-2309. doi: 10.1681/ASN.2018030245. Epub 2018 Jul 26.

PMID:
30049680
3.

Hypoxia-inducible factor-1α is a critical transcription factor for IL-10-producing B cells in autoimmune disease.

Meng X, Grötsch B, Luo Y, Knaup KX, Wiesener MS, Chen XX, Jantsch J, Fillatreau S, Schett G, Bozec A.

Nat Commun. 2018 Jan 17;9(1):251. doi: 10.1038/s41467-017-02683-x.

4.

HIF is not essential for suppression of experimental tumor growth by mTOR inhibition.

Knaup KX, Guenther R, Stoeckert J, Monti JM, Eckardt KU, Wiesener MS.

J Cancer. 2017 Jul 1;8(10):1809-1817. doi: 10.7150/jca.16486. eCollection 2017.

5.

Mutations in mitochondrial DNA causing tubulointerstitial kidney disease.

Connor TM, Hoer S, Mallett A, Gale DP, Gomez-Duran A, Posse V, Antrobus R, Moreno P, Sciacovelli M, Frezza C, Duff J, Sheerin NS, Sayer JA, Ashcroft M, Wiesener MS, Hudson G, Gustafsson CM, Chinnery PF, Maxwell PH.

PLoS Genet. 2017 Mar 7;13(3):e1006620. doi: 10.1371/journal.pgen.1006620. eCollection 2017 Mar.

6.

Depression, Anxiety, Resilience and Coping Pre and Post Kidney Transplantation - Initial Findings from the Psychiatric Impairments in Kidney Transplantation (PI-KT)-Study.

Müller HH, Englbrecht M, Wiesener MS, Titze S, Heller K, Groemer TW, Schett G, Eckardt KU, Kornhuber J, Maler JM.

PLoS One. 2015 Nov 11;10(11):e0140706. doi: 10.1371/journal.pone.0140706. eCollection 2015.

7.

Association of a coding polymorphism in Fc gamma receptor 2A and graft survival in re-transplant candidates.

Arnold ML, Fuernrohr BG, Weiß KM, Harre U, Wiesener MS, Spriewald BM.

Hum Immunol. 2015 Oct;76(10):759-64. doi: 10.1016/j.humimm.2015.09.034. Epub 2015 Sep 30.

PMID:
26429312
8.

Discordant Clinical Course of Vitamin-D-Hydroxylase (CYP24A1) Associated Hypercalcemia in Two Adult Brothers With Nephrocalcinosis.

Jobst-Schwan T, Pannes A, Schlingmann KP, Eckardt KU, Beck BB, Wiesener MS.

Kidney Blood Press Res. 2015;40(5):443-51. doi: 10.1159/000368520. Epub 2015 Aug 22. Review.

9.

Hypoxia inhibits nephrogenesis through paracrine Vegfa despite the ability to enhance tubulogenesis.

Schley G, Scholz H, Kraus A, Hackenbeck T, Klanke B, Willam C, Wiesener MS, Heinze E, Burzlaff N, Eckardt KU, Buchholz B.

Kidney Int. 2015 Dec;88(6):1283-1292. doi: 10.1038/ki.2015.214. Epub 2015 Jul 22.

PMID:
26200943
10.

Renal fibrosis is the common feature of autosomal dominant tubulointerstitial kidney diseases caused by mutations in mucin 1 or uromodulin.

Ekici AB, Hackenbeck T, Morinière V, Pannes A, Buettner M, Uebe S, Janka R, Wiesener A, Hermann I, Grupp S, Hornberger M, Huber TB, Isbel N, Mangos G, McGinn S, Soreth-Rieke D, Beck BB, Uder M, Amann K, Antignac C, Reis A, Eckardt KU, Wiesener MS.

Kidney Int. 2014 Sep;86(3):589-99. doi: 10.1038/ki.2014.72. Epub 2014 Mar 26.

11.

Renal uptake of the antiapoptotic protein survivin is mediated by megalin at the apical membrane of the proximal tubule.

Jobst-Schwan T, Knaup KX, Nielsen R, Hackenbeck T, Buettner-Herold M, Lechler P, Kroening S, Goppelt-Struebe M, Schloetzer-Schrehardt U, Fürnrohr BG, Voll RE, Amann K, Eckardt KU, Christensen EI, Wiesener MS.

Am J Physiol Renal Physiol. 2013 Sep 1;305(5):F734-44. doi: 10.1152/ajprenal.00546.2012. Epub 2013 Jul 3.

12.

Hypoxia regulates the sperm associated antigen 4 (SPAG4) via HIF, which is expressed in renal clear cell carcinoma and promotes migration and invasion in vitro.

Knaup KX, Monti J, Hackenbeck T, Jobst-Schwan T, Klanke B, Schietke RE, Wacker I, Behrens J, Amann K, Eckardt KU, Warnecke C, Wiesener MS.

Mol Carcinog. 2014 Dec;53(12):970-8. doi: 10.1002/mc.22065. Epub 2013 Jul 2.

PMID:
23818324
13.

Renal tubular HIF-2α expression requires VHL inactivation and causes fibrosis and cysts.

Schietke RE, Hackenbeck T, Tran M, Günther R, Klanke B, Warnecke CL, Knaup KX, Shukla D, Rosenberger C, Koesters R, Bachmann S, Betz P, Schley G, Schödel J, Willam C, Winkler T, Amann K, Eckardt KU, Maxwell P, Wiesener MS.

PLoS One. 2012;7(1):e31034. doi: 10.1371/journal.pone.0031034. Epub 2012 Jan 27.

14.

Hypoxia-inducible transcription factors stabilization in the thick ascending limb protects against ischemic acute kidney injury.

Schley G, Klanke B, Schödel J, Forstreuter F, Shukla D, Kurtz A, Amann K, Wiesener MS, Rosen S, Eckardt KU, Maxwell PH, Willam C.

J Am Soc Nephrol. 2011 Nov;22(11):2004-15. doi: 10.1681/ASN.2010121249. Epub 2011 Sep 15.

15.

Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD.

Bernhardt WM, Wiesener MS, Scigalla P, Chou J, Schmieder RE, Günzler V, Eckardt KU.

J Am Soc Nephrol. 2010 Dec;21(12):2151-6. doi: 10.1681/ASN.2010010116. Epub 2010 Nov 29.

16.

The GTPase RAB20 is a HIF target with mitochondrial localization mediating apoptosis in hypoxia.

Hackenbeck T, Huber R, Schietke R, Knaup KX, Monti J, Wu X, Klanke B, Frey B, Gaipl U, Wullich B, Ferbus D, Goubin G, Warnecke C, Eckardt KU, Wiesener MS.

Biochim Biophys Acta. 2011 Jan;1813(1):1-13. doi: 10.1016/j.bbamcr.2010.10.019. Epub 2010 Nov 5.

17.

Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1.

Gimm T, Wiese M, Teschemacher B, Deggerich A, Schödel J, Knaup KX, Hackenbeck T, Hellerbrand C, Amann K, Wiesener MS, Höning S, Eckardt KU, Warnecke C.

FASEB J. 2010 Nov;24(11):4443-58. doi: 10.1096/fj.10-159806. Epub 2010 Jul 12.

PMID:
20624928
18.

Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.

Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ, Maher ER.

Anticancer Res. 2009 Nov;29(11):4337-43.

19.

The lysyl oxidases LOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia: insights into cellular transformation processes mediated by HIF-1.

Schietke R, Warnecke C, Wacker I, Schödel J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt KU, Wiesener MS.

J Biol Chem. 2010 Feb 26;285(9):6658-69. doi: 10.1074/jbc.M109.042424. Epub 2009 Dec 21.

20.

Donor treatment with a PHD-inhibitor activating HIFs prevents graft injury and prolongs survival in an allogenic kidney transplant model.

Bernhardt WM, Gottmann U, Doyon F, Buchholz B, Campean V, Schödel J, Reisenbuechler A, Klaus S, Arend M, Flippin L, Willam C, Wiesener MS, Yard B, Warnecke C, Eckardt KU.

Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21276-81. doi: 10.1073/pnas.0903978106. Epub 2009 Nov 23.

21.

Novel insights into the role of the tumor suppressor von Hippel Lindau in cellular differentiation, ciliary biology, and cyst repression.

Wiesener MS, Maxwell PH, Eckardt KU.

J Mol Med (Berl). 2009 Sep;87(9):871-7. doi: 10.1007/s00109-009-0504-x. Epub 2009 Jul 24.

PMID:
19629420
22.

HIF-1 or HIF-2 induction is sufficient to achieve cell cycle arrest in NIH3T3 mouse fibroblasts independent from hypoxia.

Hackenbeck T, Knaup KX, Schietke R, Schödel J, Willam C, Wu X, Warnecke C, Eckardt KU, Wiesener MS.

Cell Cycle. 2009 May 1;8(9):1386-95. Epub 2009 May 27.

PMID:
19342889
23.

Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability.

Knaup KX, Jozefowski K, Schmidt R, Bernhardt WM, Weidemann A, Juergensen JS, Warnecke C, Eckardt KU, Wiesener MS.

Mol Cancer Res. 2009 Jan;7(1):88-98. doi: 10.1158/1541-7786.MCR-08-0288.

24.

The specific contribution of hypoxia-inducible factor-2alpha to hypoxic gene expression in vitro is limited and modulated by cell type-specific and exogenous factors.

Warnecke C, Weidemann A, Volke M, Schietke R, Wu X, Knaup KX, Hackenbeck T, Bernhardt W, Willam C, Eckardt KU, Wiesener MS.

Exp Cell Res. 2008 Jun 10;314(10):2016-27. doi: 10.1016/j.yexcr.2008.03.003. Epub 2008 Mar 18.

PMID:
18420194
25.

Hypoxia and hypoxia-inducible factor-1 alpha modulate lipopolysaccharide-induced dendritic cell activation and function.

Jantsch J, Chakravortty D, Turza N, Prechtel AT, Buchholz B, Gerlach RG, Volke M, Gläsner J, Warnecke C, Wiesener MS, Eckardt KU, Steinkasserer A, Hensel M, Willam C.

J Immunol. 2008 Apr 1;180(7):4697-705.

26.

HIF activation protects from acute kidney injury.

Weidemann A, Bernhardt WM, Klanke B, Daniel C, Buchholz B, Câmpean V, Amann K, Warnecke C, Wiesener MS, Eckardt KU, Willam C.

J Am Soc Nephrol. 2008 Mar;19(3):486-94. doi: 10.1681/ASN.2007040419. Epub 2008 Feb 6.

27.

Organ protection by hypoxia and hypoxia-inducible factors.

Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wiesener MS, Eckardt KU.

Methods Enzymol. 2007;435:221-45. Review.

PMID:
17998057
28.

The tumor gene survivin is highly expressed in adult renal tubular cells: implications for a pathophysiological role in the kidney.

Lechler P, Wu X, Bernhardt W, Campean V, Gastiger S, Hackenbeck T, Klanke B, Weidemann A, Warnecke C, Amann K, Engehausen D, Willam C, Eckardt KU, Rödel F, Wiesener MS.

Am J Pathol. 2007 Nov;171(5):1483-98.

29.

Hypoxia, via stabilization of the hypoxia-inducible factor HIF-1alpha, is a direct and sufficient stimulus for brain-type natriuretic peptide induction.

Weidemann A, Klanke B, Wagner M, Volk T, Willam C, Wiesener MS, Eckardt KU, Warnecke C.

Biochem J. 2008 Jan 1;409(1):233-42.

PMID:
17822384
30.

Erythropoietin gene expression in renal carcinoma is considerably more frequent than paraneoplastic polycythemia.

Wiesener MS, Münchenhagen P, Gläser M, Sobottka BA, Knaup KX, Jozefowski K, Jürgensen JS, Roigas J, Warnecke C, Gröne HJ, Maxwell PH, Willam C, Eckardt KU.

Int J Cancer. 2007 Dec 1;121(11):2434-42.

31.

Involvement of hypoxia-inducible transcription factors in polycystic kidney disease.

Bernhardt WM, Wiesener MS, Weidemann A, Schmitt R, Weichert W, Lechler P, Campean V, Ong AC, Willam C, Gretz N, Eckardt KU.

Am J Pathol. 2007 Mar;170(3):830-42.

32.

Characterization of a 3;6 translocation associated with renal cell carcinoma.

Foster RE, Abdulrahman M, Morris MR, Prigmore E, Gribble S, Ng B, Gentle D, Ready S, Weston PM, Wiesener MS, Kishida T, Yao M, Davison V, Barbero JL, Chu C, Carter NP, Latif F, Maher ER.

Genes Chromosomes Cancer. 2007 Apr;46(4):311-7.

33.

Identification of novel VHL targets that are associated with the development of renal cell carcinoma.

Abdulrahman M, Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, Wiesener MS, Richards FM, Johnson CM, Latif F, Maher ER.

Oncogene. 2007 Mar 8;26(11):1661-72. Epub 2006 Sep 25.

PMID:
17001320
34.

Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.

Bernhardt WM, Câmpean V, Kany S, Jürgensen JS, Weidemann A, Warnecke C, Arend M, Klaus S, Günzler V, Amann K, Willam C, Wiesener MS, Eckardt KU.

J Am Soc Nephrol. 2006 Jul;17(7):1970-8. Epub 2006 Jun 8.

35.

Hypoxia-inducible factors and tubular cell survival in isolated perfused kidneys.

Rosenberger C, Rosen S, Shina A, Bernhardt W, Wiesener MS, Frei U, Eckardt KU, Heyman SN.

Kidney Int. 2006 Jul;70(1):60-70. Epub 2006 May 17.

36.

Expression of hypoxia-inducible transcription factors in developing human and rat kidneys.

Bernhardt WM, Schmitt R, Rosenberger C, Münchenhagen PM, Gröne HJ, Frei U, Warnecke C, Bachmann S, Wiesener MS, Willam C, Eckardt KU.

Kidney Int. 2006 Jan;69(1):114-22.

37.

Role of hypoxia in the pathogenesis of renal disease.

Eckardt KU, Bernhardt WM, Weidemann A, Warnecke C, Rosenberger C, Wiesener MS, Willam C.

Kidney Int Suppl. 2005 Dec;(99):S46-51. Review.

PMID:
16336576
38.

Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.

Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER.

Cancer Res. 2005 Jun 1;65(11):4598-606.

39.

Persistent induction of HIF-1alpha and -2alpha in cardiomyocytes and stromal cells of ischemic myocardium.

Jürgensen JS, Rosenberger C, Wiesener MS, Warnecke C, Hörstrup JH, Gräfe M, Philipp S, Griethe W, Maxwell PH, Frei U, Bachmann S, Willenbrock R, Eckardt KU.

FASEB J. 2004 Sep;18(12):1415-7. Epub 2004 Jul 9.

PMID:
15247145
40.

HIF and oxygen sensing; as important to life as the air we breathe?

Wiesener MS, Maxwell PH.

Ann Med. 2003;35(3):183-90. Review.

PMID:
12822740
41.

Role of hypoxia in the pathogenesis of renal disease.

Eckardt KU, Rosenberger C, Jürgensen JS, Wiesener MS.

Blood Purif. 2003;21(3):253-7. Review.

PMID:
12784052
42.

Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia.

Brusselmans K, Compernolle V, Tjwa M, Wiesener MS, Maxwell PH, Collen D, Carmeliet P.

J Clin Invest. 2003 May;111(10):1519-27.

43.

Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.

Wiesener MS, Jürgensen JS, Rosenberger C, Scholze CK, Hörstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, Eckardt KU.

FASEB J. 2003 Feb;17(2):271-3. Epub 2002 Dec 17.

PMID:
12490539
44.

Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.

Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, Maher ER.

Cancer Res. 2002 Jul 1;62(13):3803-11. Erratum in: Cancer Res. 2015 Sep 15;75(18):3993.

45.

Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys.

Rosenberger C, Mandriota S, Jürgensen JS, Wiesener MS, Hörstrup JH, Frei U, Ratcliffe PJ, Maxwell PH, Bachmann S, Eckardt KU.

J Am Soc Nephrol. 2002 Jul;13(7):1721-32.

46.

Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma.

Wiesener MS, Seyfarth M, Warnecke C, Jürgensen JS, Rosenberger C, Morgan NV, Maher ER, Frei U, Eckardt KU.

Blood. 2002 May 15;99(10):3562-5.

47.

Erythropoietin, tumours and the von Hippel-Lindau gene: towards identification of mechanisms and dysfunction of oxygen sensing.

Wiesener MS, Eckardt KU.

Nephrol Dial Transplant. 2002 Mar;17(3):356-9. No abstract available.

PMID:
11865075
48.

The regulation of interleukin-8 by hypoxia in human macrophages--a potential role in the pathogenesis of the acute respiratory distress syndrome (ARDS).

Hirani N, Antonicelli F, Strieter RM, Wiesener MS, Ratcliffe PJ, Haslett C, Donnelly SC.

Mol Med. 2001 Oct;7(10):685-97.

49.

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU.

Cancer Res. 2001 Jul 1;61(13):5215-22.

50.

Regulation of gene expression by oxygen levels in mammalian cells.

Pugh CW, Chang GW, Cockman M, Epstein AC, Gleadle JM, Maxwell PH, Nicholls LG, O'Rourke JF, Ratcliffe PJ, Raybould EC, Tian YM, Wiesener MS, Wood M, Wykoff CC, Yeates KM.

Adv Nephrol Necker Hosp. 1999;29:191-206. Review. No abstract available.

PMID:
10561745

Supplemental Content

Loading ...
Support Center